Summary
13.28 -0.42(-3.07%)11/01/2024
Zymeworks Inc (ZYME)
Zymeworks Inc (ZYME)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.07 | 2.71 | 7.53 | 31.23 | 50.99 | 89.17 | -62.07 | 2.15 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 13.28 | |
| Open | 12.77 | |
| High | 13.49 | |
| Low | 12.39 | |
| Volume | 1,119,617 | |
| Change | -0.42 | |
| Change % | -3.07 | |
| Avg Volume (20 Days) | 387,287 | |
| Volume/Avg Volume (20 Days) Ratio | 2.89 | |
| 52 Week Range | 6.83 - 14.05 | |
| Price vs 52 Week High | -5.48% | |
| Price vs 52 Week Low | 94.44% | |
| Range | 3.99 | |
| Gap Up/Down | -1.20 | |
Fundamentals | ||
| Market Capitalization (Mln) | 886 | |
| EBIDTA | -51,618,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 47.04 | |
| Book Value | 5.9920 | |
| Earnings Per Share | -4.4450 | |
| EPS Estimate Current Quarter | -1.2300 | |
| EPS Estimate Next Quarter | -1.2800 | |
| EPS Estimate Current Year | -4.5500 | |
| EPS Estimate Next Year | -4.6300 | |
| Diluted EPS (TTM) | -4.4450 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -9.4392 | |
| Return on asset (TTM) | -0.2675 | |
| Return on equity (TTM) | -0.5921 | |
| Revenue TTM | 22,490,000 | |
| Revenue per share TTM | 0.4380 | |
| Quarterly Revenue Growth (YOY) | 0.6630 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -129,583,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.6821 | |
| Revenue Enterprise Value | 20.9230 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 46,554,000 | |
| Shares Float | 39,929,335 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.84 | |
| Institutions (%) | 82.04 | |
10/31 22:05 EST - seekingalpha.com
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by.
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by.
10/31 18:20 EST - zacks.com
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.
10/29 06:00 EST - globenewswire.com
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
10/25 06:00 EST - globenewswire.com
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.
10/21 06:00 EST - globenewswire.com
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers.
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers.
10/10 06:30 EST - globenewswire.com
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).
09/27 14:47 EST - seekingalpha.com
Zymeworks Approaching A Moment Of Truth With Zanidatamab
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.
Zymeworks Approaching A Moment Of Truth With Zanidatamab
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.
09/18 06:00 EST - globenewswire.com
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms
09/03 16:30 EST - globenewswire.com
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer.
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer.
08/01 22:58 EST - seekingalpha.com
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by.
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by.
08/01 19:11 EST - zacks.com
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.
08/01 16:10 EST - globenewswire.com
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024
07/25 16:30 EST - globenewswire.com
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.
07/22 06:00 EST - globenewswire.com
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC).
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC).
07/11 06:30 EST - globenewswire.com
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET).
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET).
06/17 06:00 EST - globenewswire.com
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.
06/10 06:00 EST - globenewswire.com
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8 million milestone payment. Zymeworks also remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales in the Asia Pacific region.
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8 million milestone payment. Zymeworks also remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales in the Asia Pacific region.
05/31 07:30 EST - accesswire.com
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.